PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
PharmAthene's presentation will be available via webcast on the company'swebsite at http://www.PharmAthene.com. A link to access the webcast will beaccessible from the Investor Relations section of the website under News &Events / Presentations. For assistance, contact Stacey Jurchison at410-269-2610.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States andits allies by developing and commercializing medical countermeasures againstbiological and chemical weapons. PharmAthene's lead product developmentprograms include:
For more information about PharmAthene, please visithttp://www.PharmAthene.com.-- SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) - a recombinant dual antigen vaccine for plague
SOURCE PharmAthene, Inc.
You May Also Like